Valika Ali, Costanzo Maria Rosa
Advocate Medical Group - Midwest Heart Specialists, Advocate Heart Institute,Oak Brook, IL, USA.
Card Fail Rev. 2017 Nov;3(2):134-139. doi: 10.15420/cfr.2017:7:1.
Sleep-disordered breathing is common in heart failure patients and is associated with increased morbidity and mortality. Central sleep apnea occurs more commonly in heart failure-reduced ejection fraction, and obstructive sleep apnea occurs more frequently in heart failure with preserved ejection fraction. Although the two types of sleep-disordered breathing have distinct pathophysiologic mechanisms, both contribute to abnormal cardiovascular consequences. Treatment with continuous positive airway pressure for obstructive sleep apnea in heart failure has been well defined, whereas treatment strategies for central sleep apnea in heart failure continue to evolve. Unilateral transvenous neurostimulation has shown promise for the treatment of central sleep apnea. In this paper, we examine the current state of knowledge of treatment options for sleep-disordered breathing in heart failure.
睡眠呼吸障碍在心力衰竭患者中很常见,且与发病率和死亡率增加相关。中枢性睡眠呼吸暂停在射血分数降低的心力衰竭患者中更常见,而阻塞性睡眠呼吸暂停在射血分数保留的心力衰竭患者中更频繁出现。尽管这两种类型的睡眠呼吸障碍有不同的病理生理机制,但都导致异常的心血管后果。心力衰竭患者阻塞性睡眠呼吸暂停采用持续气道正压通气治疗已得到明确,而心力衰竭中枢性睡眠呼吸暂停的治疗策略仍在不断发展。单侧经静脉神经刺激已显示出治疗中枢性睡眠呼吸暂停的前景。在本文中,我们探讨了心力衰竭患者睡眠呼吸障碍治疗选择的当前知识状况。